Bioarray specializes in advanced genetic testing technologies, prominently featuring Next Generation Sequencing (NGS) and liquid biopsy techniques. Their PGT-A Fast Track offers rapid results within a week, maintaining the precision of standard PGT-A tests, which enhances patient value. The company also provides a comprehensive catalog of NGS tests for clinical oncology, enabling precise treatment selection based on genetic analysis from a single sample. Additionally, Bioarray's MicroVE test assesses the vaginal and endometrial microbiota, providing critical insights that can improve embryo implantation success rates.

In the realm of molecular genetics, Bioarray is committed to delivering swift and accurate diagnoses for genetic diseases, facilitating timely and actionable information for healthcare providers and patients. Their offerings include a wide array of tests such as exome sequencing, carrier screening panels, and specialized panels for various conditions, including epilepsy and mitochondrial diseases. The integration of technologies like Cytoarray and liquid biopsy further enhances their capabilities in cancer detection and genetic counseling, ensuring that patients receive the best therapeutic options based on their genetic profiles.

Spain

Bioarray is a genetic testing provider, serving clinical partners in Europe, Latin America, MENA and Asia. Mainly using array CGH and NGS for:

- Medical Genetics: WES, WGS
- Reproductive Genetics: expanded carrier screening, preimplantation genetic testing (PGT), endometrial receptivity and prenatal diagnosis
- Oncology: somatic and germline tests, liquid biopsy
Bioarray is also a leading provider of research services, as gene expression studies based on array or RNA-seq.

Bioarray's sister company Journey Genomics launched PGD-Seq™, a kit for library preparation and data analysis, for easy PGT-M implementation for NGS labs.

Bioarray

Company Details